MedPath

Lisinopril and Hydrochlorothiazide

Lisinopril and Hydrochlorothiazide Tablets, USP, for oral use Rx Only

Approved
Approval ID

00b266d9-ac4a-e931-e063-6294a90a6a0b

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 29, 2023

Manufacturers
FDA

ST. MARY'S MEDICAL PARK PHARMACY

DUNS: 063050751

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Lisinopril and Hydrochlorothiazide Tablets

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code60760-586
Application NumberANDA076230
Product Classification
M
Marketing Category
C73584
G
Generic Name
Lisinopril and Hydrochlorothiazide Tablets
Product Specifications
Route of AdministrationORAL
Effective DateJune 29, 2023
FDA Product Classification

INGREDIENTS (6)

MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
HYDROCHLOROTHIAZIDEActive
Quantity: 12.5 mg in 1 1
Code: 0J48LPH2TH
Classification: ACTIB
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
DIBASIC CALCIUM PHOSPHATE DIHYDRATEInactive
Code: O7TSZ97GEP
Classification: IACT
LISINOPRILActive
Quantity: 10 mg in 1 1
Code: E7199S1YWR
Classification: ACTIB
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Lisinopril and Hydrochlorothiazide - FDA Drug Approval Details